|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,263.00 ILa | +3.52% |
|
+6.04% | +0.13% |
| 06-01 | Kamada Announces FDA Approval of Its New In-House Rabies Virus Neutralization Testing Laboratory | CI |
| 05-13 | Kamada Ltd., Q1 2026 Earnings Call, May 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KAMADA LTD. | Biopharmaceuticals | +3.52% | +6.04% | +0.13% | -13.69% | +19.36% | 438M |  |  | |
- Stock Market
- Stocks
- KMDA Stock
- Charts Kamada Ltd.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
